Identification of oligomers at early stages of tau aggregation in Alzheimer's disease

Cristian A. Lasagna-Reeves, Diana L. Castillo-Carranza, Urmi Sengupta, Jose Sarmiento, Juan Troncoso, George R. Jackson, Rakez Kayed

Research output: Contribution to journalArticle

179 Citations (Scopus)

Abstract

Neurofibrillary tangles (NFTs) are a pathological hallmark of Alzheimer's disease (AD); however, the relationship between NFTs and disease progression remains controversial. Analyses of tau animal models suggest that phenotypes coincide with accumulation of soluble aggregated tau species but not the accumulation of NFTs. The pathological role of prefilamentous tau aggregates, e.g., tau oligomeric intermediates, is poorly understood, in part because of methodological challenges. Here, we engineered a novel tau oligomer-specific antibody, T22, and used it to elucidate the temporal course and biochemical features of oligomers during NFT development in AD brain. We found that tau oligomers in human AD brain samples were 4-fold higher than those in the controls. We also revealed the role of oligomeric tau conformers in pretangles, neuritic plaques, and neuropil threads in the frontal cortex tissue from AD brains; this analysis uncovers a consistent code that governs tau oligomerization with regard to degree of neuronal cytopathology. These data are the first to characterize the role of tau oligomers in the natural history of NFTs, and they highlight the suitability of tau oligomers as therapeutic targets in AD and related tauopathies.

Original languageEnglish (US)
Pages (from-to)1946-1959
Number of pages14
JournalFASEB Journal
Volume26
Issue number5
DOIs
StatePublished - May 2012

Fingerprint

Neurofibrillary Tangles
Oligomers
Alzheimer Disease
Agglomeration
Brain
Neuropil Threads
Tauopathies
Amyloid Plaques
Frontal Lobe
Oligomerization
Natural History
Disease Progression
Animal Models
Animals
Phenotype
Tissue
Antibodies

Keywords

  • Conformational antibodies
  • Neurodegeneration
  • Protein misfolding
  • Tauopathies

ASJC Scopus subject areas

  • Biochemistry
  • Biotechnology
  • Genetics
  • Molecular Biology

Cite this

Lasagna-Reeves, C. A., Castillo-Carranza, D. L., Sengupta, U., Sarmiento, J., Troncoso, J., Jackson, G. R., & Kayed, R. (2012). Identification of oligomers at early stages of tau aggregation in Alzheimer's disease. FASEB Journal, 26(5), 1946-1959. https://doi.org/10.1096/fj.11-199851

Identification of oligomers at early stages of tau aggregation in Alzheimer's disease. / Lasagna-Reeves, Cristian A.; Castillo-Carranza, Diana L.; Sengupta, Urmi; Sarmiento, Jose; Troncoso, Juan; Jackson, George R.; Kayed, Rakez.

In: FASEB Journal, Vol. 26, No. 5, 05.2012, p. 1946-1959.

Research output: Contribution to journalArticle

Lasagna-Reeves, CA, Castillo-Carranza, DL, Sengupta, U, Sarmiento, J, Troncoso, J, Jackson, GR & Kayed, R 2012, 'Identification of oligomers at early stages of tau aggregation in Alzheimer's disease', FASEB Journal, vol. 26, no. 5, pp. 1946-1959. https://doi.org/10.1096/fj.11-199851
Lasagna-Reeves CA, Castillo-Carranza DL, Sengupta U, Sarmiento J, Troncoso J, Jackson GR et al. Identification of oligomers at early stages of tau aggregation in Alzheimer's disease. FASEB Journal. 2012 May;26(5):1946-1959. https://doi.org/10.1096/fj.11-199851
Lasagna-Reeves, Cristian A. ; Castillo-Carranza, Diana L. ; Sengupta, Urmi ; Sarmiento, Jose ; Troncoso, Juan ; Jackson, George R. ; Kayed, Rakez. / Identification of oligomers at early stages of tau aggregation in Alzheimer's disease. In: FASEB Journal. 2012 ; Vol. 26, No. 5. pp. 1946-1959.
@article{68fae4ac42f04836be7e85e6f179b80f,
title = "Identification of oligomers at early stages of tau aggregation in Alzheimer's disease",
abstract = "Neurofibrillary tangles (NFTs) are a pathological hallmark of Alzheimer's disease (AD); however, the relationship between NFTs and disease progression remains controversial. Analyses of tau animal models suggest that phenotypes coincide with accumulation of soluble aggregated tau species but not the accumulation of NFTs. The pathological role of prefilamentous tau aggregates, e.g., tau oligomeric intermediates, is poorly understood, in part because of methodological challenges. Here, we engineered a novel tau oligomer-specific antibody, T22, and used it to elucidate the temporal course and biochemical features of oligomers during NFT development in AD brain. We found that tau oligomers in human AD brain samples were 4-fold higher than those in the controls. We also revealed the role of oligomeric tau conformers in pretangles, neuritic plaques, and neuropil threads in the frontal cortex tissue from AD brains; this analysis uncovers a consistent code that governs tau oligomerization with regard to degree of neuronal cytopathology. These data are the first to characterize the role of tau oligomers in the natural history of NFTs, and they highlight the suitability of tau oligomers as therapeutic targets in AD and related tauopathies.",
keywords = "Conformational antibodies, Neurodegeneration, Protein misfolding, Tauopathies",
author = "Lasagna-Reeves, {Cristian A.} and Castillo-Carranza, {Diana L.} and Urmi Sengupta and Jose Sarmiento and Juan Troncoso and Jackson, {George R.} and Rakez Kayed",
year = "2012",
month = "5",
doi = "10.1096/fj.11-199851",
language = "English (US)",
volume = "26",
pages = "1946--1959",
journal = "FASEB Journal",
issn = "0892-6638",
publisher = "FASEB",
number = "5",

}

TY - JOUR

T1 - Identification of oligomers at early stages of tau aggregation in Alzheimer's disease

AU - Lasagna-Reeves, Cristian A.

AU - Castillo-Carranza, Diana L.

AU - Sengupta, Urmi

AU - Sarmiento, Jose

AU - Troncoso, Juan

AU - Jackson, George R.

AU - Kayed, Rakez

PY - 2012/5

Y1 - 2012/5

N2 - Neurofibrillary tangles (NFTs) are a pathological hallmark of Alzheimer's disease (AD); however, the relationship between NFTs and disease progression remains controversial. Analyses of tau animal models suggest that phenotypes coincide with accumulation of soluble aggregated tau species but not the accumulation of NFTs. The pathological role of prefilamentous tau aggregates, e.g., tau oligomeric intermediates, is poorly understood, in part because of methodological challenges. Here, we engineered a novel tau oligomer-specific antibody, T22, and used it to elucidate the temporal course and biochemical features of oligomers during NFT development in AD brain. We found that tau oligomers in human AD brain samples were 4-fold higher than those in the controls. We also revealed the role of oligomeric tau conformers in pretangles, neuritic plaques, and neuropil threads in the frontal cortex tissue from AD brains; this analysis uncovers a consistent code that governs tau oligomerization with regard to degree of neuronal cytopathology. These data are the first to characterize the role of tau oligomers in the natural history of NFTs, and they highlight the suitability of tau oligomers as therapeutic targets in AD and related tauopathies.

AB - Neurofibrillary tangles (NFTs) are a pathological hallmark of Alzheimer's disease (AD); however, the relationship between NFTs and disease progression remains controversial. Analyses of tau animal models suggest that phenotypes coincide with accumulation of soluble aggregated tau species but not the accumulation of NFTs. The pathological role of prefilamentous tau aggregates, e.g., tau oligomeric intermediates, is poorly understood, in part because of methodological challenges. Here, we engineered a novel tau oligomer-specific antibody, T22, and used it to elucidate the temporal course and biochemical features of oligomers during NFT development in AD brain. We found that tau oligomers in human AD brain samples were 4-fold higher than those in the controls. We also revealed the role of oligomeric tau conformers in pretangles, neuritic plaques, and neuropil threads in the frontal cortex tissue from AD brains; this analysis uncovers a consistent code that governs tau oligomerization with regard to degree of neuronal cytopathology. These data are the first to characterize the role of tau oligomers in the natural history of NFTs, and they highlight the suitability of tau oligomers as therapeutic targets in AD and related tauopathies.

KW - Conformational antibodies

KW - Neurodegeneration

KW - Protein misfolding

KW - Tauopathies

UR - http://www.scopus.com/inward/record.url?scp=84858965241&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84858965241&partnerID=8YFLogxK

U2 - 10.1096/fj.11-199851

DO - 10.1096/fj.11-199851

M3 - Article

VL - 26

SP - 1946

EP - 1959

JO - FASEB Journal

JF - FASEB Journal

SN - 0892-6638

IS - 5

ER -